MHB-088C is under clinical development by Minghui Pharmaceutical (Shanghai) and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how MHB-088C’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

MHB-088C overview

MHB-088C is under development for the treatment of advanced or metastatic solid tumors include non-small cell lung cancer, small cell lung cancer, esophageal squamous cell carcinoma (ESCC), castration-resistant prostate cancer, metastatic melanoma, metastatic colorectal cancer, pancreatic ductal adenocarcinoma, head and neck squamous cell carcinoma, metastatic hepatocellular carcinoma, metastatic ovarian cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, endometrial cancer, thyroid cancer and sarcomas. It is administered through intravenous route. The therapeutic candidate is an antibody drug-conjugate (ADC) of a humanized monoclonal antibody targeting cells expressing B7H3 (CD276) and a DNA topoisomerase I inhibitor (TOP1i) conjugated through protease-hydrolyzable linker. It is being developed based on SuperTopoi ADC platform.

For a complete picture of MHB-088C’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.